Humana (HUM) recently experienced a sharp decline in its share price, following a mix of Q4 results and the release of its 2025 financial guidance. The company saw a wider year-on-year loss in Q4 due to a drop in membership. Despite this, Humana posted quarterly earnings that beat estimates by $0.10 EPS for Q4 and reported a 13% revenue growth in the same period. A 37M patient crisis triggered a major kidney care expansion to address this healthcare concern. However, Humana's projected Medicare Advantage members are expected to decline, causing some concern. Several investment stakeholders have adjusted their stakes due to the mixed market performance. Cantor Fitzgerald reaffirmed their 'neutral' rating whilst Barclays and Royal Bank of Canada are forecasted positive futures for Humana's stock. However, Morgan Stanley lowered expectations for the healthcare giant's shares. Humana's 2024 performance, despite operational challenges, gave rise to a 'hold' rating recommendation. Lastly, Humana's CFO, Susan Diamond, announced her resignation, causing further management change and the company hired Japan Mehta as the new Chief Information Officer.
Humana HUM News Analytics from Wed, 02 Oct 2024 07:00:00 GMT to Sat, 15 Feb 2025 04:39:07 GMT -
Innovation 0
- Information 6
